<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00685750</url>
  </required_header>
  <id_info>
    <org_study_id>109752</org_study_id>
    <nct_id>NCT00685750</nct_id>
  </id_info>
  <brief_title>Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma</brief_title>
  <official_title>Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study intends to analyze the expression of specific sets of markers in tumor samples and
      in serum from patients with Non-Small Cell lung Cancer (NSCLC) or Stage III or IV melanoma.
      The data obtained in this study will be used to guide future development of immunotherapies
      for melanoma or NSCLC patients. Moreover, the analyses will contribute to definition of
      markers potentially predictive of clinical response to specific anticancer therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol posting has been updated due to a protocol amendment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrolment over the last 2 years with none in the past 1 year. No increase in the number of
    completed subjects for 1 year and no more ongoing study subjects
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Expression of tumor antigens</measure>
    <time_frame>Before and after standard treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of a pre-defined gene-expression signature to Antigen-Specific Cancer Immunotherapeutic</measure>
    <time_frame>Before and after standard treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The serum proteome</measure>
    <time_frame>Before and after standard treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of relevant markers of the pre-identified gene-expression signature as measured by immunohistochemical methods and by quantitative PCR.</measure>
    <time_frame>Before and after standard treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For NSCLC patients (where possible), the consistency of the occurrence of the gene-expression signature and tumor antigens in distinct concomitant tumor lesions obtained at the same time from the same patient.</measure>
    <time_frame>Single timepoint after standard treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For metastatic melanoma patients treated with ipilimumab explore predictive value to clinical activity of pre-identified immune-related gene-expression signature by evaluating the patient's best clinical response to this treatment.</measure>
    <time_frame>During patient's standard visits to the institution over a period of approximately 6 months after the initiation of the ipilimumab therapy.</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Lung Cancer, Non-Small Cell</condition>
  <arm_group>
    <arm_group_label>ME1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with cutaneous metastatic melanoma receiving dacarbazine or temozolomide as first line treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ME2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with cutaneous metastatic melanoma receiving first line treatment other than dacarbazine or temozolomide only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ME3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with cutaneous metastatic melanoma receiving any second-or higherline chemotherapy treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ME4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with cutaneous metastatic melanoma receiving local irradiation of cutaneous/subcutaneous tumor lesions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ME5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with cutaneous metastatic melanoma receiving local imiquimod</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non-small cell lung cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ME6</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with cutaneous metastatic melanoma receiving ipilimumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Collection of tumor and blood samples</intervention_name>
    <description>Samples will be collected before and after standard treatment</description>
    <arm_group_label>ME4</arm_group_label>
    <arm_group_label>ME1</arm_group_label>
    <arm_group_label>NSC</arm_group_label>
    <arm_group_label>ME6</arm_group_label>
    <arm_group_label>ME2</arm_group_label>
    <arm_group_label>ME3</arm_group_label>
    <arm_group_label>ME5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient (male or female) is at least 18 years of age.

          -  The investigator believes that the patient can and will comply with the requirements
             of the protocol.

          -  The patient has given his/her written informed consent to take part in the study.

          -  The investigator believes that it will be possible to obtain a tumor tissue sample of
             at least 3 mm3 before treatment and all required tumor tissues several weeks after the
             initiation of the treatment.

          -  The patient has cancer in one of the following histological types, fulfilling all of
             the characteristics listed for the respective cancer type:

        Cutaneous Melanoma, unresectable stage III or stage IV • The patient has histologically
        documented unresectable stage III or stage IV metastatic cutaneous melanoma.

        AND

        • The patient is a candidate for one of the following treatments:

          -  First-line chemotherapy with DTIC or TMZ as monotherapy [group ME1],

          -  First-line chemotherapy with an agent other than DTIC/TMZ as monotherapy or a
             combination (that may, but need not, include DTIC, TMZ, IL-2 or IFNγ) [group ME2],

          -  Second- or higherline chemotherapy with any agent or combination of agents (that may,
             but need not, include DTIC, TMZ, IL-2 or IFNγ ; i.e., systemic chemotherapy after
             isolated limb perfusion should be considered as second-line) [group ME3],

          -  Palliative irradiation of skin lesion(s)/region, irrespective of what line of
             treatment is planned [group ME4],

          -  Topical palliative treatment by imiquimod of skin lesion(s), irrespective of what line
             of treatment is planned [group ME5].

          -  First or higher line treatment with ipilimumab [group ME6].

        NSCLC, any stage if the patient is eligible for neo-adjuvant chemotherapy with subsequent
        resection • The patient has NSCLC at any stage (as defined by the International Staging
        System) if the patient is eligible for neo-adjuvant chemotherapy with subsequent resection.

        AND

        • The patient is a candidate for chemo(radio)-therapy induction doublet neoadjuvant
        chemotherapy with platinum plus a second chemotherapy drug.

        [Note: Induction radiotherapy is permitted.]

        The recruitment of patients to the NSCLC group has been ended prematurely.

        Exclusion Criteria:

          -  The patient has any family history of congenital or hereditary immunodeficiency.

          -  The patient has in the two weeks before baseline received any of the following:

          -  Chemotherapeutic agents,

          -  Immune-modulating agents such as (but not confined to) IFN-α, IL-2, BCG and
             anti-cancer therapeutic vaccines,

          -  Immunosuppressive agents such as corticosteroids [except for prednisone, or
             equivalent, &lt;0.5 mg/kg/day (absolute maximum 40 mg/day, maximum duration of treatment
             three weeks), and inhaled and topical steroids, which are allowed].

          -  The patient is currently receiving an anti cancer treatment in another clinical trial.
             However, if the patient has finished the drug administration phase of that trial and
             has entered the follow-up phase, this patient can be included.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille</city>
        <zip>13274</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>17487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ostercappeln</city>
        <state>Niedersachsen</state>
        <zip>49179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hemer</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grosshansdorf</city>
        <state>Schleswig-Holstein</state>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Siena</city>
        <state>Toscana</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Greece</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2008</study_first_submitted>
  <study_first_submitted_qc>May 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2008</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tumor antigen</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>September 29, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

